Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant <i>Acinetobacter</i> Infection in COVID-19 Patients Admitted to the Intensive Care Unit

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Antimicrobial agent</td><td class="align_center"><i>n</i> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Ampicilin</td><td class="align_center">37 (100%)</td></tr><tr><td class="align_left">Ampicilins-sulbactam</td><td class="align_center">23 (62%)</td></tr><tr><td class="align_left">Piperacilin</td><td class="align_center">37 (100%)</td></tr><tr><td class="align_left">Piperacilin-tazobactam</td><td class="align_center">36 (97%)</td></tr><tr><td class="align_left">Cefotaxime</td><td class="align_center">33 (89%)</td></tr><tr><td class="align_left">Ceftazidime</td><td class="align_center">25 (67%)</td></tr><tr><td class="align_left">Cefoperason-sulbactam</td><td class="align_center">36 (97%)</td></tr><tr><td class="align_left">Cefepim</td><td class="align_center">23 (62%)</td></tr><tr><td class="align_left">Aztreonam</td><td class="align_center">37 (100%)</td></tr><tr><td class="align_left">Imipenem</td><td class="align_center">20 (54%)</td></tr><tr><td class="align_left">Meropenem</td><td class="align_center">20 (54%)</td></tr><tr><td class="align_left">Gentamycin</td><td class="align_center">20 (54%)</td></tr><tr><td class="align_left">Amikacine</td><td class="align_center">20 (54%)</td></tr><tr><td class="align_left">Ciprofloxcin</td><td class="align_center">37 (100%)</td></tr><tr><td class="align_left">Colimycine</td><td class="align_center">1 (3%)</td></tr><tr><td class="align_left">Trimetoprim-sulfametoxazol</td><td class="align_center">21 (57%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div><i>n</i>: number of subjects.<br/></div></td></tr></table>

<div>The resistance profile of <i>Acinetobacter</i> isolates. If more than one strain was isolated in one patient, the more resistant strain was included in the analysis.</div>

Canadian Journal of Infectious Diseases and Medical Microbiology

tab2

Table 2

Table 2: Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant <i>Acinetobacter</i> Infection in COVID-19 Patients Admitted to the Intensive Care Unit 

Table 2 | Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant Acinetobacter Infection in COVID-19 Patients Admitted to the Intensive Care Unit 